CERT Certara

Certara to Participate in the Jefferies Global Healthcare Conference

Certara to Participate in the Jefferies Global Healthcare Conference

PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.

Company management will present at 1:30PM ET on Wednesday, June 7th, 2023.

A live webcast of the event will be available on Certara’s investor relations website at and will be available for replay for at least 90 days thereafter.

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries.

Investor Relations Contact:

David Deuchler

Gilmartin Group

Media Contact:

Daniel Yunger

Kekst CNC





EN
02/06/2023

Underlying

CERTCertara

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE
Free
CERT CERTARA

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic...

Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.  RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its enabled physiologically-based pharmacokinetic (PBPK) modeling predictions accepted by the U.S. FDA in lieu of clinical studies to support the new drug application (NDA) for asciminib (Scemblix®)...

March 3, 2026 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference Date and Time: Tuesday, March 3rd, 2026, at 3:10PM ET Leerink Global Healthcare Conference Date and Time: Monday, March 9th, 2026, at 8:00AM ET Barclays 28th Annual Global Healthcare ConferenceDate and Time: Tuesday, March 10th, 2026, at 1:00PM ET Live webcasts for ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Y...

Certara Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Guidance FY 2025 Revenue of $418.8M (9% growth) and Adj. EBITDA of $134.5M (10% growth) Fourth Quarter Revenue of $103.6M (3% growth) and Adj. EBITDA of $32.5M (-3% decline) FY 2026 Revenue Growth of 0-4% FY 2026 Adjusted EBITDA Margin of 30-32% FY 2026 Adjusted Diluted EPS of $0.44-$0.48 RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its fourth quarter and full fiscal year 2025 financial results. Fourth Quart...

February 26, 2026 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara to Report Fourth Quarter and Full Year 2025 Financial Results ...

Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2025 RADNOR, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the fourth quarter and full year of 2025 before market open on Thursday, February 26th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET. Investors interested in listening to the conference call are required to . It is recommended to register at least one day in adva...

January 29, 2026 1 EN
 PRESS RELEASE
Free
CERT CERTARA

Certara Reports Third Quarter 2025 Financial Results

Certara Reports Third Quarter 2025 Financial Results  Updates Full Year 2025 Financial Guidance RADNOR, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2025. Third Quarter Highlights: Revenue was $104.6 million, compared to $94.8 million in the third quarter of 2024, representing growth of 10%. Software revenue was $43.8 million, compared to $35.9 million in the third quarter of 2024, representing growth of 22%.Services revenue was $60.8 m...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch